Systemic sclerosis is an autoimmune connective tissue disease, which is characterised by
immune dysregulation and progressive fibrosis that typically affects the skin, with variable …

Background The antisynthetase syndrome consists of interstitial lung disease, arthritis,
myositis, fever, mechanic's hands, and Raynaud phenomenon in the presence of an …

Interstitial lung disease (ILD) commonly complicates the management of connective tissue
diseases (CTDs). Because the pulmonary specialist often is involved in the care of these …

Background Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis
and a leading cause of systemic sclerosis–related death. Nintedanib, a tyrosine kinase …

Background Interstitial lung disease is a known complication of rheumatoid arthritis, with a
lifetime risk of developing the disease in any individual of 7·7%. We aimed to assess the safety…

Background In the Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial,
nintedanib reduced the rate of decline in forced vital capacity (FVC) in patients with systemic …

Objective. To determine factors that influence 6-minute walk distance (6MWD) in patients
with scleroderma (systemic sclerosis, SSc)-interstitial lung disease (ILD), SSc-pulmonary …

Rationale Clinical trial design in interstitial lung diseases (ILDs) has been hampered by lack
of consensus on appropriate outcome measures for reliably assessing treatment response. …

Background: There is no consensus on the effectiveness of inhaled corticosteroids for the
treatment of chronic obstructive pulmonary disease (COPD). Purpose: To evaluate the long-…

LIP is a rare benign lymphoproliferative disorder confined to the lungs, typically associated
with an underlying disorder. In establishing a diagnosis, it is important to identify the …